{"log_id": 3995989927993207292, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0.010413, "average": 0.953406, "min": 0.668216}, "location": {"width": 192, "top": 282, "height": 27, "left": 201}, "words": "5.间质性肺病/肺炎"}, {"probability": {"variance": 1e-06, "average": 0.99943, "min": 0.994193}, "location": {"width": 833, "top": 305, "height": 38, "left": 251}, "words": "本品单药治疗或与其他化疗药物联合时曾有间质性肺病和肺炎的报告(参见【不"}, {"probability": {"variance": 7e-06, "average": 0.998703, "min": 0.983631}, "location": {"width": 878, "top": 354, "height": 34, "left": 206}, "words": "良反应】)。应当监测患者有无提示间质性肺病或肺炎可能的相应肺部症状。出现提"}, {"probability": {"variance": 3.3e-05, "average": 0.99706, "min": 0.976914}, "location": {"width": 880, "top": 399, "height": 37, "left": 205}, "words": "示≥ NCI CTCAE3级肺部症状并且这些症状提示有间质性肺病/肺炎可能的患者,应当"}, {"probability": {"variance": 3e-06, "average": 0.998602, "min": 0.995835}, "location": {"width": 94, "top": 452, "height": 28, "left": 205}, "words": "停用本品"}, {"probability": {"variance": 0, "average": 0.999697, "min": 0.999243}, "location": {"width": 105, "top": 548, "height": 27, "left": 206}, "words": "6QT延长"}, {"probability": {"variance": 0.002143, "average": 0.99136, "min": 0.721543}, "location": {"width": 834, "top": 573, "height": 34, "left": 253}, "words": "在晚期癌症患者中开展的非对照、开放性拉帕替尼剂量递增研究中观察到QT延"}, {"probability": {"variance": 0.00229, "average": 0.988485, "min": 0.713633}, "location": {"width": 881, "top": 617, "height": 37, "left": 204}, "words": "长。有QTc延长或可能发生QTc延长的患者应当慎用本品。这些情况包括低钾血症或"}, {"probability": {"variance": 0.005054, "average": 0.987481, "min": 0.555274}, "location": {"width": 881, "top": 664, "height": 34, "left": 205}, "words": "低镁血症患者,先天性长QT综合征患者,使用抗心律失常药物或其他导致QT延长的"}, {"probability": {"variance": 1.7e-05, "average": 0.998357, "min": 0.97889}, "location": {"width": 881, "top": 710, "height": 33, "left": 205}, "words": "药物和累积大剂量蒽环类药物治疗的患者。使用拉帕替尼治疗前必须纠正低钾血症或"}, {"probability": {"variance": 0, "average": 0.999605, "min": 0.999352}, "location": {"width": 94, "top": 762, "height": 26, "left": 207}, "words": "低镁血症"}, {"probability": {"variance": 0.000503, "average": 0.990925, "min": 0.931572}, "location": {"width": 167, "top": 856, "height": 28, "left": 206}, "words": "7.药物相互作用"}, {"probability": {"variance": 1.9e-05, "average": 0.998368, "min": 0.972861}, "location": {"width": 834, "top": 896, "height": 35, "left": 254}, "words": "由于有增加或降低本品暴露量的风险,应当小心谨慎与CYP3A4抑制剂或诱导剂联"}, {"probability": {"variance": 1e-06, "average": 0.999173, "min": 0.996455}, "location": {"width": 344, "top": 946, "height": 29, "left": 205}, "words": "用治疗(参见【药物相互作用】)"}, {"probability": {"variance": 0.000742, "average": 0.991925, "min": 0.890099}, "location": {"width": 334, "top": 1004, "height": 28, "left": 205}, "words": "8.对驾驶和操作机器能力的影响"}, {"probability": {"variance": 0, "average": 0.917847, "min": 0.917847}, "location": {"width": 89, "top": 1019, "height": 31, "left": 921}, "words": " EUANGDONG"}, {"probability": {"variance": 0.011778, "average": 0.969553, "min": 0.508019}, "location": {"width": 818, "top": 1033, "height": 54, "left": 255}, "words": "目前尚未开展本品对驾驶和机械操作能力影响的研究。根据的定"}, {"probability": {"variance": 0.001375, "average": 0.990492, "min": 0.800729}, "location": {"width": 758, "top": 1083, "height": 42, "left": 207}, "words": "预测本品会对这些能力产生有害影响。应考虑患者的临床状况本"}, {"probability": {"variance": 3.2e-05, "average": 0.996426, "min": 0.977765}, "location": {"width": 824, "top": 1088, "height": 91, "left": 206}, "words": "综合判断患者进行驾驶或机器操作时的判断力、运动能力或认知力"}, {"probability": {"variance": 0, "average": 0.986202, "min": 0.986202}, "location": {"width": 25, "top": 1150, "height": 26, "left": 955}, "words": "米"}, {"probability": {"variance": 0, "average": 0.95708, "min": 0.95708}, "location": {"width": 24, "top": 1144, "height": 23, "left": 1053}, "words": "G"}, {"probability": {"variance": 0, "average": 0.999787, "min": 0.999234}, "location": {"width": 321, "top": 1240, "height": 31, "left": 215}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0, "average": 0.999655, "min": 0.999539}, "location": {"width": 47, "top": 1294, "height": 26, "left": 210}, "words": "孕妇"}, {"probability": {"variance": 3e-06, "average": 0.999211, "min": 0.992926}, "location": {"width": 835, "top": 1335, "height": 33, "left": 251}, "words": "尚无妊娠妇女应用本品的充分数据和良好的对照研究。本品对妊娠妇女的影响还不"}, {"probability": {"variance": 1e-06, "average": 0.999371, "min": 0.995173}, "location": {"width": 841, "top": 1379, "height": 36, "left": 207}, "words": "清楚。只有当治疗获益超过对胎儿造成的可能危害时,本品才能考虑应用于妊娠妇"}, {"probability": {"variance": 5e-06, "average": 0.998632, "min": 0.991032}, "location": {"width": 539, "top": 1429, "height": 29, "left": 208}, "words": "女。育龄妇女接受本品治疗时应采取足够的避孕措施"}, {"probability": {"variance": 4.7e-05, "average": 0.997713, "min": 0.960344}, "location": {"width": 837, "top": 1472, "height": 32, "left": 256}, "words": "针对怀孕大鼠和兔所进行的研究显示,本品并不具致畸性,但在器官形成期给药"}], "language": 3}